Friday, 16 October 2026European Markets

VAN DE VELDE And KERING Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - van de velde (van.br) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
van de velde (van.br) €33.20 6.98% 22.83%
kering (ker.pa) €494.70 3.04% 24.04%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. van de velde (van.br)

6.98% forward dividend yield and 22.83% return on equity

van de velde nv, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear for women worldwide. it operates through two segments, business to business (b2b) and direct to consumer (d2c). the company offers its products under the primadonna, marie jo, andres sarda, and lingerie styling brands. it also operates retail websites; stores; and boutiques and department stores. the company was founded in 1919 and is headquartered in schellebelle, belgium. van de velde nv is a subsidiary of van de velde holding nv.

earnings per share

as for profitability, van de velde has a trailing twelve months eps of €2.77.

pe ratio

van de velde has a trailing twelve months price to earnings ratio of 11.99. meaning, the purchaser of the share is investing €11.99 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.83%.

volatility

van de velde's last week, last month's, and last quarter's current intraday variation average was 0.34%, 0.04%, and 0.76%.

van de velde's highest amplitude of average volatility was 0.57% (last week), 0.94% (last month), and 0.76% (last quarter).

moving average

van de velde's value is under its 50-day moving average of €33.33 and above its 200-day moving average of €33.13.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, van de velde's stock is considered to be oversold (<=20).

yearly top and bottom value

van de velde's stock is valued at €33.20 at 02:30 est, way below its 52-week high of €37.25 and way above its 52-week low of €29.45.

more news about van de velde.

2. kering (ker.pa)

3.04% forward dividend yield and 24.04% return on equity

kering sa offers ready-to-wear products apparel and accessories for men and women in france, the asia-pacific, western europe, north america, japan, and internationally. it also offers leather goods and shoes; watches and jewelry; eyewear products; and fragrances and cosmetics. the company provides gucci, saint laurent, bottega veneta, balenciaga, alexander mcqueen, brioni, boucheron, pomellato, dodo, qeelin, and kering eyewear brands. the company was formerly known as ppr sa and changed its name to kering sa in june 2013. kering sa was founded in 1963 and is based in paris, france.

earnings per share

as for profitability, kering has a trailing twelve months eps of €27.84.

pe ratio

kering has a trailing twelve months price to earnings ratio of 17.77. meaning, the purchaser of the share is investing €17.77 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.04%.

moving average

kering's worth is below its 50-day moving average of €500.42 and under its 200-day moving average of €531.47.

yearly top and bottom value

kering's stock is valued at €494.70 at 02:30 est, way below its 52-week high of €603.60 and way above its 52-week low of €427.55.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, kering's stock is considered to be overbought (>=80).

more news about kering.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com